Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (41)	7/29/2006 4:21:55 PM
From: rareearth42	Read Replies (3) \| Respond to of 285

I fail to understand what all of you see in CRME. Management has made, IMHO, some mind-numbingly poor decisions in the past, particularly related to oxypurinol, and I have no confidence in them. Development of a safe and effective antiarrhythmic drug is extremely challenging and risky. If one had, in the past, bet against all the small companies doing this, it would have been a very successful investment strategy. CRME might get lucky, but I doubt it. I think there are much better opportunities in biotech right now. RE42 P.S. PGS, is that you? Did you graduate? You should still be "P", unless your investments have paid off handsomely......